Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 3
2007 4
2008 2
2009 6
2010 7
2011 5
2012 6
2013 5
2014 5
2015 5
2016 6
2017 6
2018 15
2019 6
2020 3
2021 6
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators. Richardson PG, et al. Among authors: fulciniti m. N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660812 Free PMC article. Clinical Trial.
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Gulla A, et al. Among authors: fulciniti m. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23. Blood Cancer Discov. 2021. PMID: 34568832 Free PMC article.
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M. Yao Y, et al. Among authors: fulciniti m. Blood. 2023 Jun 8;141(23):2841-2852. doi: 10.1182/blood.2022018885. Blood. 2023. PMID: 36877894 Free PMC article.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Among authors: fulciniti m. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Walker BA, et al. Among authors: fulciniti m. Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Blood. 2018. PMID: 29884741 Free PMC article.
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Samur MK, et al. Among authors: fulciniti m. Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5. Nat Commun. 2021. PMID: 33558511 Free PMC article. Clinical Trial.
Biological Insights into Myeloma and Other B Cell Malignancies.
Fulciniti M, Amodio N, Cea M, Maiso P, Azab AK. Fulciniti M, et al. Biomed Res Int. 2016;2016:5218093. doi: 10.1155/2016/5218093. Epub 2016 Feb 16. Biomed Res Int. 2016. PMID: 26989685 Free PMC article. No abstract available.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. Samur MK, et al. Among authors: fulciniti m. Blood. 2023 Apr 6;141(14):1724-1736. doi: 10.1182/blood.2022017094. Blood. 2023. PMID: 36603186
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
Morelli E, Fulciniti M, Samur MK, Ribeiro CF, Wert-Lamas L, Henninger JE, Gullà A, Aktas-Samur A, Todoerti K, Talluri S, Park WD, Federico C, Scionti F, Amodio N, Bianchi G, Johnstone M, Liu N, Gramegna D, Maisano D, Russo NA, Lin C, Tai YT, Neri A, Chauhan D, Hideshima T, Shammas MA, Tassone P, Gryaznov S, Young RA, Anderson KC, Novina CD, Loda M, Munshi NC. Morelli E, et al. Among authors: fulciniti m. Blood. 2023 Jan 26;141(4):391-405. doi: 10.1182/blood.2022016892. Blood. 2023. PMID: 36126301 Free PMC article.
Deep Response in Multiple Myeloma: A Critical Review.
Fulciniti M, Munshi NC, Martinez-Lopez J. Fulciniti M, et al. Biomed Res Int. 2015;2015:832049. doi: 10.1155/2015/832049. Epub 2015 Dec 10. Biomed Res Int. 2015. PMID: 26783530 Free PMC article. Review.
91 results